Mariner
SNDX icon

Mariner’s Syndax Pharmaceuticals SNDX Stock Holding History

Mariner’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.71M Buy
73,199
+18,212
+33% +$396K ﹤0.01% 1611
2025
Q4 		$1.15M Buy
54,987
+31,547
+135% +$550K ﹤0.01% 1849
2025
Q3 		$361K Buy
+23,440
New +$307K ﹤0.01% 2666

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

Mariner's SNDX Position: Q1 2026 in Review

Mariner increased its Syndax Pharmaceuticals (SNDX) stake by 33% in Q1 2026, buying an estimated $396K and bringing the position to 73,199 shares worth $1.71M. The position accounts for ﹤0.01% of the portfolio, ranked #1611.

Mariner first reported a position in SNDX in Q3 2025 and has held it in 3 quarters since. 246 funds tracked by Wall St. Rank hold SNDX as of Q1 2026.

  • Mariner held 73,199 shares of Syndax Pharmaceuticals worth $1.71M as of Q1 2026.
  • Mariner bought 18,212 Syndax Pharmaceuticals shares in Q1 2026, an estimated $396K.
  • Syndax Pharmaceuticals made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #1611 holding.
  • Mariner first reported a position in Syndax Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • 246 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.